Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response

Science

Volumn 285, Issue 5428, 1999, Pages 747-750

  Zhong, Qing ^a   Chen, Chi Fen ^a   Li, Shang ^a   Chen, Yumay ^a   Wang, Chuan Cheng ^a   Xiao, Jun ^a   Chen, Phang Lang ^a   Sharp, Z Dave ^a   Lee, Wen Hwa ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA BINDING PROTEIN; GENE PRODUCT; MESYLIC ACID METHYL ESTER;

ARTICLE; BREAST CANCER; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IRRADIATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION;

BRCA1 PROTEIN; CELL CYCLE PROTEINS; CELL NUCLEUS; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; GAMMA RAYS; GENES, BRCA1; HUMANS; METHYL METHANESULFONATE; MUTAGENS; MUTATION; NUCLEAR PROTEINS; RAD51 RECOMBINASE; RECOMBINATION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033618621     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5428.747     Document Type: Article

References (42)

1. J. M. Hall et al., Science 250, 1684 (1990); Y. Miki et al., ibid. 266, 66 (1994).
2. J. M. Hall et al., Science 250, 1684 (1990); Y. Miki et al., ibid. 266, 66 (1994).
3. X. Yu, L. C. Wu, A. M. Bowcock, A. Aronheim, R. Baer, J. Biol. Chem. 273, 25388 (1998); A. K. Wong et al., Oncogene 17, 2279 (1998); S. Li et al., J. Biol. Chem. 274, 11334 (1999).
4. X. Yu, L. C. Wu, A. M. Bowcock, A. Aronheim, R. Baer, J. Biol. Chem. 273, 25388 (1998); A. K. Wong et al., Oncogene 17, 2279 (1998); S. Li et al., J. Biol. Chem. 274, 11334 (1999).
5. X. Yu, L. C. Wu, A. M. Bowcock, A. Aronheim, R. Baer, J. Biol. Chem. 273, 25388 (1998); A. K. Wong et al., Oncogene 17, 2279 (1998); S. Li et al., J. Biol. Chem. 274, 11334 (1999).
6. L. C. Gowen, A. V. Avrutskaya, A. M. Latour, B. H. Koller, S. A. Leadon, Science 281, 1009 (1998).
7. R. Scully et al., Cell 90, 425 (1997); R. Scully et al., ibid. 88, 265 (1997).
8. R. Scully et al., Cell 90, 425 (1997); R. Scully et al., ibid. 88, 265 (1997).
9. X. L. Xu et al., Mol. Cell 3, 389 (1999).
10. Y. Chen et al., Science 270, 789 (1995); Y. Chen et al., Cancer Res. 56, 3168 (1996).
11. Y. Chen et al., Science 270, 789 (1995); Y. Chen et al., Cancer Res. 56, 3168 (1996).
12. Polyclonal antibodies were obtained by using the following bacterially expressed and purified GST fusion proteins as antigens: GST-hRad50-15A5, containing amino acids 211 through 575 of hRad50; GST-MM, containing amino acids 82 through 582 of hMre11; GST-NBS1, containing amino acids 12 through 754 of p95; GST-hRad51, containing full-length hRad51; and GST alone (for anti-GST mAb 8G11), to generate polyclonal or monoclonal antibodies (25). BRCA1 mAb's 6B4 and 17F8 were described in (18). BRCA1 mAb Ab-1 and rabbit α-hRad51 antibodies were from Oncogene Research Product (Cambridge, MA). Affinity-purified rabbit α-BRCA1 antibody (C-20) and α-HA antibody (Y-11) were from Santa Cruz Biotechnology (Santa Cruz, CA).
13. J. E. Haber, Cell 95, 583 (1998).
14. W. E. Raymond and N. Kleckner, Nucleic Acids Res. 21, 3851 (1993).
15. T. T. Paull and M. Gellert, Mol. Cell 1, 969 (1998); K. M. Trujillo, S. S. Yuan, E. Y. Lee, P. Sung, J. Biol. Chem. 273, 21447 (1998); M. Furuse et al., EMBO J. 17, 6412 (1998); T. Usui et al., Cell 95, 705 (1998), S. Moreau, J. R. Ferguson, L. S. Symington, Mol. Cell. Biol. 19, 556 (1999).
16. T. T. Paull and M. Gellert, Mol. Cell 1, 969 (1998); K. M. Trujillo, S. S. Yuan, E. Y. Lee, P. Sung, J. Biol. Chem. 273, 21447 (1998); M. Furuse et al., EMBO J. 17, 6412 (1998); T. Usui et al., Cell 95, 705 (1998), S. Moreau, J. R. Ferguson, L. S. Symington, Mol. Cell. Biol. 19, 556 (1999).
17. T. T. Paull and M. Gellert, Mol. Cell 1, 969 (1998); K. M. Trujillo, S. S. Yuan, E. Y. Lee, P. Sung, J. Biol. Chem. 273, 21447 (1998); M. Furuse et al., EMBO J. 17, 6412 (1998); T. Usui et al., Cell 95, 705 (1998), S. Moreau, J. R. Ferguson, L. S. Symington, Mol. Cell. Biol. 19, 556 (1999).
18. T. T. Paull and M. Gellert, Mol. Cell 1, 969 (1998); K. M. Trujillo, S. S. Yuan, E. Y. Lee, P. Sung, J. Biol. Chem. 273, 21447 (1998); M. Furuse et al., EMBO J. 17, 6412 (1998); T. Usui et al., Cell 95, 705 (1998), S. Moreau, J. R. Ferguson, L. S. Symington, Mol. Cell. Biol. 19, 556 (1999).
19. T. T. Paull and M. Gellert, Mol. Cell 1, 969 (1998); K. M. Trujillo, S. S. Yuan, E. Y. Lee, P. Sung, J. Biol. Chem. 273, 21447 (1998); M. Furuse et al., EMBO J. 17, 6412 (1998); T. Usui et al., Cell 95, 705 (1998), S. Moreau, J. R. Ferguson, L. S. Symington, Mol. Cell. Biol. 19, 556 (1999).
20. Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); C. M. Weemaes, D. F. Smeets, C. J. van der Burgt, Int. J. Radiat. Biol. 66, S185 (1994); I. van der Burgt, K. H. Chrzanowska, D. Smeets, C. Weemaes, J. Med. Genet. 33, 153 (1996); R. Varon et al., Cell 93, 467 (1998).
21. Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); C. M. Weemaes, D. F. Smeets, C. J. van der Burgt, Int. J. Radiat. Biol. 66, S185 (1994); I. van der Burgt, K. H. Chrzanowska, D. Smeets, C. Weemaes, J. Med. Genet. 33, 153 (1996); R. Varon et al., Cell 93, 467 (1998).
22. Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); C. M. Weemaes, D. F. Smeets, C. J. van der Burgt, Int. J. Radiat. Biol. 66, S185 (1994); I. van der Burgt, K. H. Chrzanowska, D. Smeets, C. Weemaes, J. Med. Genet. 33, 153 (1996); R. Varon et al., Cell 93, 467 (1998).
23. Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); C. M. Weemaes, D. F. Smeets, C. J. van der Burgt, Int. J. Radiat. Biol. 66, S185 (1994); I. van der Burgt, K. H. Chrzanowska, D. Smeets, C. Weemaes, J. Med. Genet. 33, 153 (1996); R. Varon et al., Cell 93, 467 (1998).
24. J. P. Carney et al., Cell 93, 477 (1998).
25. B. E. Nelms, R. S. Maser, J. F. MacKay, M. G. Lagally, J. H. J. Petrini, Science 280, 590 (1998).
26. G. M. Dolganov et al., Mol. Cell. Biol. 16, 4832 (1996).
27. R. S. Maser, K. J. Monsen, B. E. Nelms, J. H. J. Petrini, ibid. 17, 6087 (1997).
28. Q. Zhong and W.-H. Lee, unpublished results.
29. The procedure for indirect immunofluorescence staining was adopted and slightly modified from that in (25). In a typical staining experiment, 500 to 1000 cells were counted. For the foci-containing cells, only nuclei containing >10 foci were counted as a foci-containing cell Each experiment was repeated at least three times, and the results were reproducible with the antibodies indicated here. The results did not vary according to the conditions of fixation. The foci formation studies were performed following different time courses after irradiation (at 1, 3, 6, 8, and 12 hours). Because all of the studied foci show relatively high quality and quantity at 8 hours after irradiation, the results at this time point are mostly used as representatives here.
30. H. K. Chew, A. A. Farmer, W.-H. Lee, in Breast Cancer, A. Bowcock, Ed. (Humana, Totowa, NJ, 1998), pp. 225-246.
31. C. E. Tomlinson et al., Cancer Res. 58, 3237 (1998).
32. L. J. C. Wu et al., Nature Genet. 14, 430 (1996).
33. M. S. Chapman and I. M. Verma, Nature 382, 678 (1996).
34. S. K. Sharan et al., ibid. 386, 804 (1997); P. L. Chen et al., Proc. Natl Acad. Sci. U.S.A. 95, 5287 (1998).
35. S. K. Sharan et al., ibid. 386, 804 (1997); P. L. Chen et al., Proc. Natl Acad. Sci. U.S.A. 95, 5287 (1998).
36. J. Chen et al., Mol. Cell 2, 317 (1998).
37. C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 396, 643 (1998); H. Zhang, G. Tombline, B. Weber, Cell 92, 433 (1998).
38. C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 396, 643 (1998); H. Zhang, G. Tombline, B. Weber, Cell 92, 433 (1998).
39. Q. Zhong et al., Cancer Res. 57, 4225 (1997).
40. 1), cells were harvested. To obtain cells in M phase, we added nocodazole (0.4 μg/ml) to the culture medium for 10 hours before harvest.
41. Constructs based on plasmid pcDNA3.1 (Invitrogen, San Diego, CA) were used for lipofectin-mediated transfection of HCC1937 cells with BRCA1 cDNA. Cells were harvested after 48 hours for immunoprecipitation and protein immunoblot analysis. Parallel cultures were treated with 0.1% MMS for 50 min, and surviving cells were counted after 8 days. The experiments were repeated at least three times, and the results were consistent.
42. We thank J. Petrini for rabbit antisera to hRad50, P. Garza and D. Jones for antibody production, and N. Ting and T. Boyer for critical reading. Supported by grants from NIH (CA 58183 and CA 30195), the McDermott endowment (W.H.L.), and the Susan G. Komen Foundation for Breast Cancer Research (P.L.C.).